2020-09-14 19:12 |
Strengthening theranostics or radionuclide therapy in Pakistan
/ Khan, Irfan Ullah (INMOL Institute of Nuclear Medicine and Oncology)
In this project, we are interested to strengthen theranostics or radionuclide therapy in Pakistan. Due to its ability of targeting only cancerous cells, the field of theranostics is rapidly emerging worldwide and in developed countries, it is considered as real cancer diagnosis and treatment modality. [...]
MED-027.-
Geneva : CERN, 2020 - 6.
Fulltext: DOCX;
|
Notice détaillée - Notices similaires
|
2020-09-14 15:50 |
Facilities and Expertise in nuclear medicine
/ Khan, Irfan Ullah (INMOL Institute of Nuclear Medicine and Oncology)
This technical note is submitted following the accession of Pakistan to the MEDICIS collaboration as endorsed at the 5th Board, and required as follow-up..
MED-026.-
Geneva : CERN, 2020 - 2.
clinical qualification for radioisotopes: DOC;
|
Notice détaillée - Notices similaires
|
2020-02-17 09:50 |
Notice détaillée - Notices similaires
|
2019-09-16 08:10 |
Notice détaillée - Notices similaires
|
2019-03-15 16:24 |
Imaging of iron metabolism
Iron is an essential and critical trace metal in the human body as it is involved in many vital processes like oxygen transport and redox reactions. However, excess iron is toxic and can cause oxidative stress (Dev, 2017). [...]
MED-023.-
Geneva : CERN, 2019 - 2.
Fulltext: PDF;
|
Notice détaillée - Notices similaires
|
2019-03-15 16:05 |
Notice détaillée - Notices similaires
|
2019-03-12 18:16 |
Notice détaillée - Notices similaires
|
2019-03-12 11:47 |
Notice détaillée - Notices similaires
|
2019-03-07 15:20 |
No-carrier-added 175Yb production at MEDICIS from external ILL target
Introduction & background: (state of the art and goal/motivation for the project) High-energy β- emitter 90Y(T1/2 :64 h ; Eβmean = 934 keV) and medium energy β- emitter 177Lu (T1/2: 6.73 d ; Eβ-mean = 154 keV) are the most widely used radionuclides for therapeutic radiopharmaceuticals. Monte Carlo simulations have shown that 177Lu might be more appropriate than 90Y for the treatment of minimal residual disease [1] and practical experience in clinics have proven the favorable properties of 177Lu regarding the significant reduction of undesired side effects to healthy organs (e.g [...]
MED-019.-
Geneva : CERN, 2019 - 2.
Fulltext: PDF;
|
Notice détaillée - Notices similaires
|
2019-03-07 15:16 |
No-carrier-added 169Er production at MEDICIS from target irradiated at ILL
Introduction & background: (state of the art and goal/motivation for the project) To date, 169Er (carrier-added) is used for the treatment of chronic rheumatoid arthritis in order to eliminate diseased synovium through irradiation and to improve joint function [1, 2]. However, its decay properties (T1/2 = 9.4 d, Eβmean = 219 keV) are very promising for radionuclide therapy of metastasized cancer diseases. [...]
MED-018.-
Geneva : CERN, 2019 - 2.
Fulltext: PDF;
|
Notice détaillée - Notices similaires
|